Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Sandoz Receives FDA Approval for ENZEEVU™
Sandoz has secured FDA approval for ENZEEVU™ (aflibercept-abzv), a biosimilar to EYLEA®, to treat retinal conditions like wet age-related macular degeneration (AMD) and diabetic retinopathy. This approval strengthens Sandoz’s U.S. biosimilar portfolio, offering a cost-effective alternative for managing retinal diseases.…
AMD Explained: Tips for Safeguarding Your Vision
The eyes are often called the windows to the soul, but what happens when those windows become cloudy and blurred? That’s the reality for millions suffering from age-related macular degeneration (AMD), which can rob you of your precious eyesight as…
FDA Notifies Ocugen to Begin Expanded Access Program RP
The FDA has authorized Ocugen, Inc. to launch an expanded access program (EAP) for patients aged 18 and older with retinitis pigmentosa (RP), providing early access to its promising gene therapy candidate, OCU400. The treatment has shown encouraging results in…
Bausch + Lomb’s TENEO Laser Achieves Strong LASIK Outcomes
Bausch + Lomb recently published the results of a pivotal clinical trial for its TENEO™ Excimer Laser in the Journal of Refractive Surgery. This study, which played a crucial role in securing U.S. FDA approval for the device in January…
Eyenovia and SGN Nanopharma to Develop Dry Eye Treatment
Eyenovia and SGN Nanopharma have announced a new collaboration to develop a treatment for chronic dry eye disease. Eyenovia, known for its two FDA-approved products and a late-stage asset in pediatric progressive myopia, will work with SGN Nanopharma to develop…
Novaliq’s Vevizye® Receives Positive CHMP Opinion for DED
Novaliq announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending the granting of a marketing authorization for Vevizye® in the European Union. This therapy is designed to treat moderate…
Elon Musk’s Blindsight Implant Faces Skepticism from Researchers
Elon Musk recently announced on X that Blindsight, a cortical implant to restore vision, would have low resolution at first “but may ultimately exceed normal human vision.” Skepticism from University of Washington Research New research from the University of Washington…
Link Between Proteins in Tears and Pain After Eye Surgery
In a study published in the Journal of Proteome Research, researchers from Oregon Health & Science University (OHSU) have identified a connection between specific proteins found in patients’ tears and persistent pain experienced months after eye surgery. This discovery could…
New Insights on Retinoblastoma Treatment
Recent research presented at the Society of NeuroInterventional Surgery’s (SNIS) 21st Annual Meeting underscores significant improvements in treating retinoblastoma, a rare eye cancer affecting young children. The study reveals that advancements in treatment over the past 15 years have notably…
Nicox Concludes U.S. Recruitment for Phase 3 NCX 470 Trial
Nicox announced the recruitment and randomization of the final patient in the United States for its Denali Phase 3 trial of NCX 470. This milestone marks a significant step in evaluating the safety and efficacy of NCX 470 for patients…